Reconstitution of antibody-dependent phagocytosis in fibroblasts expressing Fc gamma receptor IIIB and the complement receptor type 3. 1994

J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor 48109.

In this study, we test the hypothesis that co-expression of both the complement receptor type 3 (CR3; CD11b/CD18) and Fc gamma receptor type IIIB (Fc gamma RIIIB) (CD16) are sufficient to mediate Ab-dependent phagocytosis. To explore the roles of these receptors in a simple and well-defined in vitro system, stable transfectants of fibroblasts expressing either CR3, Fc gamma RIIIB, or the combination of CR3 and Fc gamma RIIIB were generated. Cells not expressing either receptor, but exposed to the transfection protocol, were used as controls. Cell surface expression of CR3 and/or Fc gamma RIIIB were confirmed by using both flow cytometry and epifluorescence microscopy. The cell lines were analyzed for their ability to bind and internalize opsonized erythrocytes. Cells expressing both CR3 and Fc gamma RIIIB were able to both bind and phagocytose IgG-coated erythrocytes. In contrast, cells expressing CR3 only were able to phagocytose yeast, but not to bind nor phagocytose IgG-coated erythrocytes. Similarly, cells expressing Fc gamma RIIIB only were able to bind IgG-coated erythrocytes, but not to phagocytose either the erythrocytes or yeast. These studies demonstrate that, although CR3 does not participate in Ab-dependent recognition, it can complement the function of Fc gamma RIIIB to effect Ab-dependent phagocytosis. These studies also suggest that one mechanism for glycosylphosphatidylinositol-linked proteins to mediate intracellular functions is through interactions with transmembrane proteins.

UI MeSH Term Description Entries
D007152 Immunologic Capping An energy dependent process following the crosslinking of B CELL ANTIGEN RECEPTORS by multivalent ligands (bivalent anti-antibodies, LECTINS or ANTIGENS), on the B-cell surface. The crosslinked ligand-antigen receptor complexes collect in patches which flow to and aggregate at one pole of the cell to form a large mass - the cap. The caps may then be endocytosed or shed into the environment. Capping, Immunologic,Immunological Capping,Capping, Immunological
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011940 Receptor Aggregation Chemically stimulated aggregation of cell surface receptors, which potentiates the action of the effector cell. Aggregation, Receptor,Capping, Receptor,Receptor Capping
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D016177 Macrophage-1 Antigen An adhesion-promoting leukocyte surface membrane heterodimer. The alpha subunit consists of the CD11b ANTIGEN and the beta subunit the CD18 ANTIGEN. The antigen, which is an integrin, functions both as a receptor for complement 3 and in cell-cell and cell-substrate adhesive interactions. CR3 Receptor,Complement 3 Receptor,Integrin alphaMbeta2,Mac-1 Antigen,Receptor, Complement 3,Adhesive Receptor Mac-1,Integrin alpha(M)beta(2),Integrin alpha-M beta-2,Mac-1 Adhesive Receptor,Mac-1 Receptor,Mo1 Antigen Receptor,Mo1 Glycoprotein Receptor,Receptor, CR3,Receptor, Mo1 Antigen,Receptor, Mo1 Glycoprotein,Adhesive Receptor, Mac-1,Antigen Receptor, Mo1,Antigen, Macrophage-1,Glycoprotein Receptor, Mo1,Integrin alpha M beta 2,Mac 1 Adhesive Receptor,Mac 1 Antigen,Mac 1 Receptor,Macrophage 1 Antigen,Receptor, Mac-1 Adhesive,alpha-M beta-2, Integrin,alphaMbeta2, Integrin
D016475 3T3 Cells Cell lines whose original growing procedure consisted being transferred (T) every 3 days and plated at 300,000 cells per plate (J Cell Biol 17:299-313, 1963). Lines have been developed using several different strains of mice. Tissues are usually fibroblasts derived from mouse embryos but other types and sources have been developed as well. The 3T3 lines are valuable in vitro host systems for oncogenic virus transformation studies, since 3T3 cells possess a high sensitivity to CONTACT INHIBITION. 3T3 Cell,Cell, 3T3,Cells, 3T3
D017261 Glycosylphosphatidylinositols Compounds containing carbohydrate or glycosyl groups linked to phosphatidylinositols. They anchor GPI-LINKED PROTEINS or polysaccharides to cell membranes. GPI Membrane Anchor,GPI Membrane Anchors,Glycosyl-Phosphatidylinositol Membrane Protein Anchor,Glycosylated Phosphatidylinositol,Glycosylphosphatidylinositol Anchor,Glycosylphosphatidylinositol Anchors,Phosphatidylinositol Glycan,Gly-PtdIns,Glycoinositol Phospholipid Membrane Anchor,Glycosyl-Phosphatidylinositol,Glycosyl-Phosphatidylinositol Membrane Protein Anchors,Glycosylated Phosphatidylinositols,Glycosylphosphatidylinositol,Glycosylphosphatidylinositol Linkage,PI-Glycan,Anchor, GPI Membrane,Anchor, Glycosylphosphatidylinositol,Anchors, GPI Membrane,Anchors, Glycosylphosphatidylinositol,Glycan, Phosphatidylinositol,Glycosyl Phosphatidylinositol,Glycosyl Phosphatidylinositol Membrane Protein Anchor,Glycosyl Phosphatidylinositol Membrane Protein Anchors,Linkage, Glycosylphosphatidylinositol,Membrane Anchor, GPI,Membrane Anchors, GPI,PI Glycan,Phosphatidylinositol, Glycosylated,Phosphatidylinositols, Glycosylated

Related Publications

J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
April 1995, Journal of molecular biology,
J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
June 1995, The Journal of clinical investigation,
J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
April 2016, Journal of immunology (Baltimore, Md. : 1950),
J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
January 2000, Journal of immunology (Baltimore, Md. : 1950),
J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
May 1978, The Journal of laboratory and clinical medicine,
J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
January 1987, International journal of immunopharmacology,
J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
October 2008, Journal of immunology (Baltimore, Md. : 1950),
J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
June 1998, Current opinion in infectious diseases,
J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
September 1997, Cancer research,
J C Krauss, and PooH, and W Xue, and L Mayo-Bond, and R F Todd, and H R Petty
January 1994, Medicina,
Copied contents to your clipboard!